Jerusalem based Gamida Cell Ltd., a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that they have signed for $40 million financing to support the ongoing Phase 3 trial of the Company’s FDA Breakthrough Designated clinical-stage product, NiCord. NiCord facilitates bone marrow transplantation.

For more informations, see:
https://www.gamida-cell.com/press_release/gamida-cell-announces-40-million-private-financing/

See Gamida Cell Ltd.’s site: https://www.gamida-cell.com